CitedEvidence
User Settings

A phase I trial of an anti-pka oligonucleotide (GEM231) administered with weekly CPT-11

0

TL;DRAbstract

2074

Chat with Paper

AI Agents for this Paper

2074

Keywords

MedicinePharmacologyInternal medicineOncology

Chat

Click to start Chat